Xenon Pharmaceuticals (XENE) Current Leases (2019 - 2026)

Xenon Pharmaceuticals (XENE) has 8 years of Current Leases data on file, last reported at $1.6 million in Q1 2026.

• On a quarterly basis, Current Leases rose 12.95% year-over-year to $1.6 million in Q1 2026; TTM through Mar 2026 was $1.6 million, a 12.95% increase from a year earlier, with the FY2025 full-year figure at $1.5 million, up 11.91% from the prior year.
• Current Leases for Q1 2026 stood at $1.6 million, up from $1.5 million in the prior quarter.
• Over the last five years, Current Leases for XENE reached as high as $1.6 million in Q1 2026 and fell as low as $488000.0 in Q4 2022.
• Historically, Current Leases has averaged $1.3 million across 5 years, with a median of $1.4 million in 2024.
• Across the five-year window, Current Leases fell 19.34% in 2022 and surged 166.19% in 2023, its largest moves.
• Year by year, Current Leases stood at $488000.0 in 2022, then jumped by 166.19% to $1.3 million in 2023, then advanced by 5.39% to $1.4 million in 2024, then rose by 11.91% to $1.5 million in 2025, then grew by 1.89% to $1.6 million in 2026.
• Per Business Quant data, the three most recent Current Leases figures were $1.6 million in Q1 2026, $1.5 million in Q4 2025, and $1.5 million in Q3 2025.